一项随机、双盲、安慰剂对照的1期临床试验,局部泛赖氨酸氧化酶抑制剂PXS-6302用于成熟疤痕

IF 14.6 1区 医学 Q1 CELL BIOLOGY
Natalie Morellini, Peijun Gong, Suzanne Rea, Helen Douglas, Phuoc Hao Ho, Barry Cense, Brendan F. Kennedy, Wolfgang Jarolimek, Brett Charlton, Alison Findlay, Joanna Leadbetter, Fiona M. Wood, Mark W. Fear
{"title":"一项随机、双盲、安慰剂对照的1期临床试验,局部泛赖氨酸氧化酶抑制剂PXS-6302用于成熟疤痕","authors":"Natalie Morellini,&nbsp;Peijun Gong,&nbsp;Suzanne Rea,&nbsp;Helen Douglas,&nbsp;Phuoc Hao Ho,&nbsp;Barry Cense,&nbsp;Brendan F. Kennedy,&nbsp;Wolfgang Jarolimek,&nbsp;Brett Charlton,&nbsp;Alison Findlay,&nbsp;Joanna Leadbetter,&nbsp;Fiona M. Wood,&nbsp;Mark W. Fear","doi":"10.1126/scitranslmed.adv2471","DOIUrl":null,"url":null,"abstract":"<div >Skin scars remain a substantial clinical challenge because of their impact on appearance and psychological well-being. Lysyl oxidases catalyze collagen cross-linking, a key factor in scar development. Here, we report a randomized, double-blind, placebo-controlled phase 1 study to assess the safety and tolerability of PXS-6302, a topical pan–lysyl oxidase inhibitor, in treating mature scars (ACTRN12621001545853). Fifty participants were enrolled across two cohorts: Cohort 1 (open label, <i>n</i> = 8) applied PXS-6302 (2%) daily, and cohort 2 (<i>n</i> = 42) was randomized 1:1 to apply PXS-6302 (2%) or placebo three times per week to a 10-square-centimeter area of scar for 3 months. No severe adverse events (AEs) were reported. Mild to moderate localized skin reactions were the only treatment-related AEs, leading to discontinuation by six participants. Treatment with PXS-6302 three times per week reduced lysyl oxidase activity by 66% and decreased hydroxyproline (a marker for collagen) and total protein concentrations in scar biopsies compared with placebo. Optical coherence tomography showed increased microvessel density and tissue attenuation [a marker of extracellular matrix (ECM) composition] at 3 months compared with the baseline, suggesting ECM remodeling toward unscarred skin architecture. No significant differences in Patient Observer Scar Assessment Scale (POSAS) scores were observed between groups after 90 days of treatment once baseline imbalances were accounted for. Together, these data showed that topical pan–lysyl oxidase inhibition was generally well tolerated and altered some measures of the ECM in mature scars, supporting the advancement of this treatment into phase 2 trials.</div>","PeriodicalId":21580,"journal":{"name":"Science Translational Medicine","volume":"17 815","pages":""},"PeriodicalIF":14.6000,"publicationDate":"2025-09-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"A randomized, double-blind, placebo-controlled phase 1 trial of the topical pan–lysyl oxidase inhibitor PXS-6302 in mature scars\",\"authors\":\"Natalie Morellini,&nbsp;Peijun Gong,&nbsp;Suzanne Rea,&nbsp;Helen Douglas,&nbsp;Phuoc Hao Ho,&nbsp;Barry Cense,&nbsp;Brendan F. Kennedy,&nbsp;Wolfgang Jarolimek,&nbsp;Brett Charlton,&nbsp;Alison Findlay,&nbsp;Joanna Leadbetter,&nbsp;Fiona M. Wood,&nbsp;Mark W. Fear\",\"doi\":\"10.1126/scitranslmed.adv2471\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div >Skin scars remain a substantial clinical challenge because of their impact on appearance and psychological well-being. Lysyl oxidases catalyze collagen cross-linking, a key factor in scar development. Here, we report a randomized, double-blind, placebo-controlled phase 1 study to assess the safety and tolerability of PXS-6302, a topical pan–lysyl oxidase inhibitor, in treating mature scars (ACTRN12621001545853). Fifty participants were enrolled across two cohorts: Cohort 1 (open label, <i>n</i> = 8) applied PXS-6302 (2%) daily, and cohort 2 (<i>n</i> = 42) was randomized 1:1 to apply PXS-6302 (2%) or placebo three times per week to a 10-square-centimeter area of scar for 3 months. No severe adverse events (AEs) were reported. Mild to moderate localized skin reactions were the only treatment-related AEs, leading to discontinuation by six participants. Treatment with PXS-6302 three times per week reduced lysyl oxidase activity by 66% and decreased hydroxyproline (a marker for collagen) and total protein concentrations in scar biopsies compared with placebo. Optical coherence tomography showed increased microvessel density and tissue attenuation [a marker of extracellular matrix (ECM) composition] at 3 months compared with the baseline, suggesting ECM remodeling toward unscarred skin architecture. No significant differences in Patient Observer Scar Assessment Scale (POSAS) scores were observed between groups after 90 days of treatment once baseline imbalances were accounted for. Together, these data showed that topical pan–lysyl oxidase inhibition was generally well tolerated and altered some measures of the ECM in mature scars, supporting the advancement of this treatment into phase 2 trials.</div>\",\"PeriodicalId\":21580,\"journal\":{\"name\":\"Science Translational Medicine\",\"volume\":\"17 815\",\"pages\":\"\"},\"PeriodicalIF\":14.6000,\"publicationDate\":\"2025-09-10\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Science Translational Medicine\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.science.org/doi/10.1126/scitranslmed.adv2471\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"CELL BIOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Science Translational Medicine","FirstCategoryId":"3","ListUrlMain":"https://www.science.org/doi/10.1126/scitranslmed.adv2471","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CELL BIOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

皮肤疤痕仍然是一个实质性的临床挑战,因为他们的外观和心理健康的影响。赖氨酸氧化酶催化胶原交联,这是疤痕形成的关键因素。在这里,我们报告了一项随机、双盲、安慰剂对照的1期研究,以评估PXS-6302治疗成熟疤痕的安全性和耐受性,PXS-6302是一种局部泛赖氨酸氧化酶抑制剂(ACTRN12621001545853)。50名参与者分为两个队列:队列1(开放标签,n = 8)每天应用PXS-6302(2%),队列2 (n = 42)按1:1随机分组,每周三次应用PXS-6302(2%)或安慰剂,持续3个月。无严重不良事件(ae)报告。轻度至中度局部皮肤反应是唯一与治疗相关的不良反应,导致6名参与者停药。与安慰剂相比,PXS-6302治疗每周3次,可使赖氨酸氧化酶活性降低66%,并降低疤痕活检中羟脯氨酸(胶原蛋白的标志物)和总蛋白浓度。光学相干断层扫描显示,与基线相比,3个月时微血管密度增加,组织衰减[细胞外基质(ECM)组成的标志],表明ECM向无疤痕皮肤结构重塑。治疗90天后,一旦考虑到基线失衡,两组之间的患者观察疤痕评估量表(POSAS)评分没有显著差异。总之,这些数据表明局部泛赖氨酸氧化酶抑制通常耐受性良好,并改变了成熟疤痕中ECM的一些测量,支持该治疗进入2期试验。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
A randomized, double-blind, placebo-controlled phase 1 trial of the topical pan–lysyl oxidase inhibitor PXS-6302 in mature scars
Skin scars remain a substantial clinical challenge because of their impact on appearance and psychological well-being. Lysyl oxidases catalyze collagen cross-linking, a key factor in scar development. Here, we report a randomized, double-blind, placebo-controlled phase 1 study to assess the safety and tolerability of PXS-6302, a topical pan–lysyl oxidase inhibitor, in treating mature scars (ACTRN12621001545853). Fifty participants were enrolled across two cohorts: Cohort 1 (open label, n = 8) applied PXS-6302 (2%) daily, and cohort 2 (n = 42) was randomized 1:1 to apply PXS-6302 (2%) or placebo three times per week to a 10-square-centimeter area of scar for 3 months. No severe adverse events (AEs) were reported. Mild to moderate localized skin reactions were the only treatment-related AEs, leading to discontinuation by six participants. Treatment with PXS-6302 three times per week reduced lysyl oxidase activity by 66% and decreased hydroxyproline (a marker for collagen) and total protein concentrations in scar biopsies compared with placebo. Optical coherence tomography showed increased microvessel density and tissue attenuation [a marker of extracellular matrix (ECM) composition] at 3 months compared with the baseline, suggesting ECM remodeling toward unscarred skin architecture. No significant differences in Patient Observer Scar Assessment Scale (POSAS) scores were observed between groups after 90 days of treatment once baseline imbalances were accounted for. Together, these data showed that topical pan–lysyl oxidase inhibition was generally well tolerated and altered some measures of the ECM in mature scars, supporting the advancement of this treatment into phase 2 trials.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Science Translational Medicine
Science Translational Medicine CELL BIOLOGY-MEDICINE, RESEARCH & EXPERIMENTAL
CiteScore
26.70
自引率
1.20%
发文量
309
审稿时长
1.7 months
期刊介绍: Science Translational Medicine is an online journal that focuses on publishing research at the intersection of science, engineering, and medicine. The goal of the journal is to promote human health by providing a platform for researchers from various disciplines to communicate their latest advancements in biomedical, translational, and clinical research. The journal aims to address the slow translation of scientific knowledge into effective treatments and health measures. It publishes articles that fill the knowledge gaps between preclinical research and medical applications, with a focus on accelerating the translation of knowledge into new ways of preventing, diagnosing, and treating human diseases. The scope of Science Translational Medicine includes various areas such as cardiovascular disease, immunology/vaccines, metabolism/diabetes/obesity, neuroscience/neurology/psychiatry, cancer, infectious diseases, policy, behavior, bioengineering, chemical genomics/drug discovery, imaging, applied physical sciences, medical nanotechnology, drug delivery, biomarkers, gene therapy/regenerative medicine, toxicology and pharmacokinetics, data mining, cell culture, animal and human studies, medical informatics, and other interdisciplinary approaches to medicine. The target audience of the journal includes researchers and management in academia, government, and the biotechnology and pharmaceutical industries. It is also relevant to physician scientists, regulators, policy makers, investors, business developers, and funding agencies.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信